Cipla Ltd

Cipla Ltd Share Price Today

Cipla Limited was founded in 1935 as Chemical, Industrial, and Pharmaceutical Laboratories Ltd. Khwaja Abdul Hamied, Cipla's founder, granted the corporation royalty-free access to all of its patents and unique formulations for various pharmaceuticals and treatments. On August 17, 1935, the corporation was incorporated as a public limited company. Cipla began with its initial production facility at Bombay Central in 1936 and now has over 40 state-of-the-art manufacturing facilities worldwide, including in the United States, China, and South Africa, as well as India. 

Cipla Ltd Manufacturing Facilities

Cipla started its operations with a production facility at Bombay Central in the year 1936. Over the years, it has expanded its footprint to encompass more than 40 state-of-the-art manufacturing facilities globally, located not only in India but also in countries such as the United States, China, and South Africa.

Business Segments of Cipla

• Cipla is India's third-largest pharmaceutical firm. Finished medications are one of its largest product categories. The firm offers a diverse range of over 1,500 pharmaceuticals in over 50 dosage forms and 65 therapeutic areas. 
• It is the market leader in respiratory and urology therapy and India's second-largest exporter to emerging countries, including South Africa.
• Cipla is also a large manufacturer of APIs (active pharmaceutical ingredients). It assists large generic pharmaceutical businesses with their supply chains.
• Geographically, India accounts for little less than 50% of total revenues, with North America accounting for around 22% as of September 2023.
• In 2021, it had around 55 subsidiary firms. The list contains both domestic subsidiaries (Meditab Specialities Pvt. Ltd. and Cipla BioTec Pvt. Ltd.) and overseas subsidiaries (Cipla BioTec South Africa (Pty) Limited and InvaGen Pharmaceuticals Inc).

Key Personnel of Cipla

Mr. Vohra has been Cipla's MD and Global CEO since September 2016. He formerly worked with Eicher Motors, PepsiCo, and Dr. Reddy's Laboratories. With a remarkable career spanning over two decades in both India and the United States, Mr. Vohra has a thorough grasp of the many components of the global pharmaceutical industry.

Cipla Ltd Milestones

• Cipla capitalised on the medicine scarcity during World War II in 1941 by making excellent chemicals. In 1952, the business established its first research branch. 
• In 1968, it produced ampicillin for the first time in India. 
• In 1972, Cipla established the Agricultural Research Division in Bangalore to conduct scientific cultivation of therapeutic plants. 
• In 1985, the US FDA authorised the pharmaceutical company's bulk medication production facilities. 

Cipla has grown to become one of the world's most recognised brands, and several facilities and products have been introduced throughout the years.

Corporate Actions of Cipla Ltd

Cipla share price history is quite fascinating as the firm has made the following important business initiatives during the last several years:

• Bonus Shares
• Cipla last announced a bonus share offering in 2006 with a 3:2 ratio.
• Split Stocks
• Cipla divided its shares from Rs.10 to Rs.2 in 2004.
• Cipla has not conducted any rights issues or share buybacks.

You can find the Cipla share price BSE & NSE today on BlinkX.

Cipla Ltd Mergers and Acquisitions

• During fiscal year 2018, Anmarate (Pty) Limited was bought in South Africa as part of a drive to improve its OTC portfolio.
• Cipla (EU) Limited, Cipla's UK subsidiary, successfully acquired InvaGen Pharmaceuticals Inc. and Exelan Pharmaceuticals Inc. in February 2016.
• In July 2013, Cipla paid ZAR 4507 million (Rs.2,707 crore) for the whole outstanding share capital of Cipla Medpro South Africa Ltd.

Management Outlook of Cipla Ltd

From 2020 to 2023, Cipla optimised business methods, reorganised its portfolio, and increased its competitive position in key markets. Throughout the epidemic, Cipla expanded its capacities to assure universal access to quality medications. The firm has also engaged in automation and digitisation to achieve long-term efficiencies in its portfolio selection, production, supply chain, and quality operations.